Cormedix Inc (CRMD) 8.86 $CRMD
Immunomedics (IMMU) Provides Update on Lead ADC Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 1:45PM CDT
Immunomedics, Inc. (IMMU) provided an update on its lead ADC candidate, sacituzumab govitecan.
CRMD: 8.86 (-0.28), BIIB: 423.57 (+1.46), IMMU: 4.14 (-0.04)
Illumina (ILMN) Tops Q1 Earnings, Revenues; EPS View Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 9:15AM CDT
Illumina (ILMN) has started off 2015 on a positive note with remarkable first-quarter results, which mark the 14th consecutive quarter of sequential revenue growth.
CRMD: 8.86 (-0.28), BIIB: 423.57 (+1.46), CYTX: 0.96 (-0.09), ILMN: 190.04 (-9.27)
Actavis' Botox Upper Limb Spasticity Label Expanded by FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 3:08PM CDT
Actavis' (ACT) Botox has been granted further FDA approval; adds upper limb spasticity to its label.
CRMD: 8.86 (-0.28), BIIB: 423.57 (+1.46), ACT: 295.22 (+0.69), AVEO: 2.04 (+0.12)
4 Stocks Under $10 Making Big Moves
at The Street - Thu Apr 16, 1:11PM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
CRMD: 8.86 (-0.28), MCEP: 6.13 (+0.11), NTLS: 5.46 (+0.17), OCLS: 0.84 (-0.01)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Thu Apr 09, 8:11AM CDT
MEMP: 16.95 (-0.16), CRMD: 8.86 (-0.28), INO: 10.39 (-0.09), AMCN: 4.43 (+0.44), QURE: 26.15 (-1.44), ALTR: 42.78 (-0.46), BIOS: 5.23 (+0.04), NVGN: 7.40 (-0.30), ZNGA: 2.51 (+0.02), DGLY: 13.13 (+0.08), INFN: 19.79 (-0.43), EXEL: 3.12 (+0.05)
CorMedix Institutes Program to Reduce Neutrolin® Cost of Goods; Reports on Strategic Review Process Managed by Evercore
PR Newswire - Thu Apr 09, 7:00AM CDT
CorMedix Inc. (NYSE MKT: CRMD), a global biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases, today announced a significant new program aimed at enhancing long term market competitiveness by substantially reducing the cost of goods of Neutrolin® Catheter Lock Solution through a more efficient, custom synthesis of the active ingredient taurolidine.
CRMD: 8.86 (-0.28)
CorMedix: High Probability Of Phase 3 Success?
Pharma Investor - at Seeking Alpha - Wed Apr 08, 12:49PM CDT
CRMD: 8.86 (-0.28)
Healthcare stock screen of the month: Price extended, poor fundamentals
Seeking Alpha - at Seeking Alpha - Wed Apr 08, 12:05PM CDT
CRMD: 8.86 (-0.28), ADXS: 22.18 (+0.10), CYTX: 0.96 (-0.09), CNDO: 4.09 (-0.09), AMRN: 2.34 (-0.05), AVEO: 2.04 (+0.12), NVGN: 7.40 (-0.30), AXN: 1.77 (+0.01), NYMX: 1.32 (-0.08), DRRX: 2.19 (+0.10), RIGL: 4.24 (+0.07), CAPN: 6.99 (-0.29)
The Top-Performing Biotech Stock During a Sizzling First Quarter
at The Street - Wed Apr 01, 8:30AM CDT
That was one crazy first quarter for the biotech sector. Here's where biotech stocks stand on April Fool's Day.
CRMD: 8.86 (-0.28), BIIB: 423.57 (+1.46), ESPR: 100.53 (-2.60), FMI: 48.71 (-0.96), ANTH: 4.79 (+0.10), XBI: 232.63 (-0.32), IBB: 363.84 (-0.66), TRIL: 20.67 (-2.53)
CorMedix Receives Audit Opinion with Going Concern Explanation
PR Newswire - Tue Mar 31, 5:00PM CDT
CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases, today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2014, which was filed on March 12, 2015, the audited financial statements for the year ended December 31, 2014 contained in the Form 10-K contained an audit opinion from its independent registered public accounting firm which includes a going concern qualification.
CRMD: 8.86 (-0.28)
3 Small Cap Pharma Stocks Set to Surge Following Q1 Earnings - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Tue Mar 31, 1:33PM CDT
Healthcare has been a great place to invest in over the last few years, but pharmaceuticals have done even better...3 pharma stocks
CRMD: 8.86 (-0.28), IHE: 178.66 (-0.18), IYH: 157.86 (+0.08), HZNP: 30.96 (+0.10), STML: 16.51 (+0.13)
Will CorMedix (CRMD) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 31, 7:03AM CDT
Will CorMedix (CRMD) Continue to Surge Higher?
CRMD: 8.86 (-0.28)
CorMedix (CRMD): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 30, 7:34AM CDT
CorMedix (CRMD) in the Medical – Biomed/Gene space is seeing solid earnings estimate revisions and has a great Zacks Industry Rank.
CRMD: 8.86 (-0.28)
Technical Scrutiny on Biotech Stocks -- Exact Sciences, Galena Biopharma, Alkermes, Seattle Genetics, and CorMedix
PR Newswire - Thu Mar 26, 8:00AM CDT
Editor Note: For more information about this release, please scroll to bottom.
CRMD: 8.86 (-0.28), SGEN: 36.92 (-0.32), GALE: 1.39 (unch), EXAS: 22.28 (+0.24), ALKS: 62.60 (-0.24)
CorMedix Announces Effectiveness of Registration Statements for Shares Underlying Publicly Traded Warrants
PR Newswire - Fri Mar 20, 7:00AM CDT
CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases, today announced that the registration statements for the shares of its common stock underlying its publicly traded warrants with CUSIP number (No.21900C118) have both been declared effective by the Securities and Exchange Commission. Holders of publicly traded warrants who wish to exercise their warrants will receive freely tradable shares of common stock upon presentation of a properly completed exercise notice and full payment for exercise. As previously reported, the expiration date for these publicly traded warrants is April 30, 2015.
CRMD: 8.86 (-0.28)
CorMedix (CRMD) Looks Good: Stock Moves 8.7% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 18, 8:25AM CDT
CorMedix (CRMD) was a big mover last session, with shares rising roughly 9% on the day.
CRMD: 8.86 (-0.28), AFFX: 12.57 (-0.13)
Borrow Costs Elevated On CorMedix
Interactive Brokers - at Seeking Alpha - Tue Mar 17, 2:09AM CDT
CorMedix, Inc. (NYSEMKT: CRMD ) continues to be a difficult borrow as demand has far exceeded the lendable supply. Over the past two weeks the amount of shares traded in the cash market has been well above historical averages while the amount of...
CRMD: 8.86 (-0.28), EYES: 13.26 (-0.06), SHAK: 62.00 (+2.00), MELA: 1.52 (-0.14), GME: 40.24 (+0.16), AMRN: 2.34 (-0.05), AXN: 1.77 (+0.01), FXCM: 2.13 (+0.02), WBAI: 16.75 (-0.46), RESN: 3.77 (-0.06), WPRT: 4.39 (+0.01), RIG: 16.85 (-0.18), CYTX: 0.96 (-0.09), CEN: 16.93 (+0.07), CAPN: 6.99 (-0.29)
CorMedix's (CRMD) CEO Randy Milby on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Mar 13, 4:36PM CDT
CRMD: 8.86 (-0.28)
Seeking Alpha's Biotech Weekly: Deeper Looks At Orexigen, Pharmacyclics, And Acadia
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 13, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
ACT: 295.22 (+0.69), PCYC: 256.98 (-0.77), ITEK: 4.80 (-0.02), REDX: (), PTX: 7.44 (-0.05), CLDX: 28.95 (+1.08), ILMN: 190.04 (-9.27), IDGX: (), ACAD: 38.55 (-0.20), TRGT: 2.30 (-0.02), CLLS: 31.30 (-0.91), EXAC: 24.15 (+0.15), ABBV: 64.52 (+0.91), CRMD: 8.86 (-0.28), AGMX: (), ZGNX: 1.63 (-0.02), VVUS: 2.50 (+0.04), SPPI: 5.98 (+0.04), GSK: 46.57 (-0.67), OREX: 7.39 (+0.22), SQNM: 4.47 (+0.08), IRWD: 15.07 (-0.19), GILD: 104.18 (-1.02), MRK: 57.69 (+0.03), OHRP: 2.72 (+0.08), TEVA: 63.01 (-1.15)
Immunomedics (IMMU) Provides Update on Lead ADC Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 1:45PM CDT
Immunomedics, Inc. (IMMU) provided an update on its lead ADC candidate, sacituzumab govitecan.
CRMD: 8.86 (-0.28), BIIB: 423.57 (+1.46), IMMU: 4.14 (-0.04)
Illumina (ILMN) Tops Q1 Earnings, Revenues; EPS View Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 9:15AM CDT
Illumina (ILMN) has started off 2015 on a positive note with remarkable first-quarter results, which mark the 14th consecutive quarter of sequential revenue growth.
CRMD: 8.86 (-0.28), BIIB: 423.57 (+1.46), CYTX: 0.96 (-0.09), ILMN: 190.04 (-9.27)
Actavis' Botox Upper Limb Spasticity Label Expanded by FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 3:08PM CDT
Actavis' (ACT) Botox has been granted further FDA approval; adds upper limb spasticity to its label.
CRMD: 8.86 (-0.28), BIIB: 423.57 (+1.46), ACT: 295.22 (+0.69), AVEO: 2.04 (+0.12)
4 Stocks Under $10 Making Big Moves
at The Street - Thu Apr 16, 1:11PM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
CRMD: 8.86 (-0.28), MCEP: 6.13 (+0.11), NTLS: 5.46 (+0.17), OCLS: 0.84 (-0.01)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Thu Apr 09, 8:11AM CDT
MEMP: 16.95 (-0.16), CRMD: 8.86 (-0.28), INO: 10.39 (-0.09), AMCN: 4.43 (+0.44), QURE: 26.15 (-1.44), ALTR: 42.78 (-0.46), BIOS: 5.23 (+0.04), NVGN: 7.40 (-0.30), ZNGA: 2.51 (+0.02), DGLY: 13.13 (+0.08), INFN: 19.79 (-0.43), EXEL: 3.12 (+0.05)
CorMedix Institutes Program to Reduce Neutrolin® Cost of Goods; Reports on Strategic Review Process Managed by Evercore
PR Newswire - Thu Apr 09, 7:00AM CDT
CorMedix Inc. (NYSE MKT: CRMD), a global biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases, today announced a significant new program aimed at enhancing long term market competitiveness by substantially reducing the cost of goods of Neutrolin® Catheter Lock Solution through a more efficient, custom synthesis of the active ingredient taurolidine.
CRMD: 8.86 (-0.28)
CorMedix: High Probability Of Phase 3 Success?
Pharma Investor - at Seeking Alpha - Wed Apr 08, 12:49PM CDT
CRMD: 8.86 (-0.28)
Healthcare stock screen of the month: Price extended, poor fundamentals
Seeking Alpha - at Seeking Alpha - Wed Apr 08, 12:05PM CDT
CRMD: 8.86 (-0.28), ADXS: 22.18 (+0.10), CYTX: 0.96 (-0.09), CNDO: 4.09 (-0.09), AMRN: 2.34 (-0.05), AVEO: 2.04 (+0.12), NVGN: 7.40 (-0.30), AXN: 1.77 (+0.01), NYMX: 1.32 (-0.08), DRRX: 2.19 (+0.10), RIGL: 4.24 (+0.07), CAPN: 6.99 (-0.29)
The Top-Performing Biotech Stock During a Sizzling First Quarter
at The Street - Wed Apr 01, 8:30AM CDT
That was one crazy first quarter for the biotech sector. Here's where biotech stocks stand on April Fool's Day.
CRMD: 8.86 (-0.28), BIIB: 423.57 (+1.46), ESPR: 100.53 (-2.60), FMI: 48.71 (-0.96), ANTH: 4.79 (+0.10), XBI: 232.63 (-0.32), IBB: 363.84 (-0.66), TRIL: 20.67 (-2.53)
CorMedix Receives Audit Opinion with Going Concern Explanation
PR Newswire - Tue Mar 31, 5:00PM CDT
CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases, today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2014, which was filed on March 12, 2015, the audited financial statements for the year ended December 31, 2014 contained in the Form 10-K contained an audit opinion from its independent registered public accounting firm which includes a going concern qualification.
CRMD: 8.86 (-0.28)
3 Small Cap Pharma Stocks Set to Surge Following Q1 Earnings - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Tue Mar 31, 1:33PM CDT
Healthcare has been a great place to invest in over the last few years, but pharmaceuticals have done even better...3 pharma stocks
CRMD: 8.86 (-0.28), IHE: 178.66 (-0.18), IYH: 157.86 (+0.08), HZNP: 30.96 (+0.10), STML: 16.51 (+0.13)
Will CorMedix (CRMD) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 31, 7:03AM CDT
Will CorMedix (CRMD) Continue to Surge Higher?
CRMD: 8.86 (-0.28)
CorMedix (CRMD): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 30, 7:34AM CDT
CorMedix (CRMD) in the Medical – Biomed/Gene space is seeing solid earnings estimate revisions and has a great Zacks Industry Rank.
CRMD: 8.86 (-0.28)
Technical Scrutiny on Biotech Stocks -- Exact Sciences, Galena Biopharma, Alkermes, Seattle Genetics, and CorMedix
PR Newswire - Thu Mar 26, 8:00AM CDT
Editor Note: For more information about this release, please scroll to bottom.
CRMD: 8.86 (-0.28), SGEN: 36.92 (-0.32), GALE: 1.39 (unch), EXAS: 22.28 (+0.24), ALKS: 62.60 (-0.24)
CorMedix Announces Effectiveness of Registration Statements for Shares Underlying Publicly Traded Warrants
PR Newswire - Fri Mar 20, 7:00AM CDT
CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases, today announced that the registration statements for the shares of its common stock underlying its publicly traded warrants with CUSIP number (No.21900C118) have both been declared effective by the Securities and Exchange Commission. Holders of publicly traded warrants who wish to exercise their warrants will receive freely tradable shares of common stock upon presentation of a properly completed exercise notice and full payment for exercise. As previously reported, the expiration date for these publicly traded warrants is April 30, 2015.
CRMD: 8.86 (-0.28)
CorMedix (CRMD) Looks Good: Stock Moves 8.7% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 18, 8:25AM CDT
CorMedix (CRMD) was a big mover last session, with shares rising roughly 9% on the day.
CRMD: 8.86 (-0.28), AFFX: 12.57 (-0.13)
Borrow Costs Elevated On CorMedix
Interactive Brokers - at Seeking Alpha - Tue Mar 17, 2:09AM CDT
CorMedix, Inc. (NYSEMKT: CRMD ) continues to be a difficult borrow as demand has far exceeded the lendable supply. Over the past two weeks the amount of shares traded in the cash market has been well above historical averages while the amount of...
CRMD: 8.86 (-0.28), EYES: 13.26 (-0.06), SHAK: 62.00 (+2.00), MELA: 1.52 (-0.14), GME: 40.24 (+0.16), AMRN: 2.34 (-0.05), AXN: 1.77 (+0.01), FXCM: 2.13 (+0.02), WBAI: 16.75 (-0.46), RESN: 3.77 (-0.06), WPRT: 4.39 (+0.01), RIG: 16.85 (-0.18), CYTX: 0.96 (-0.09), CEN: 16.93 (+0.07), CAPN: 6.99 (-0.29)
CorMedix's (CRMD) CEO Randy Milby on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Mar 13, 4:36PM CDT
CRMD: 8.86 (-0.28)
Seeking Alpha's Biotech Weekly: Deeper Looks At Orexigen, Pharmacyclics, And Acadia
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 13, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
ACT: 295.22 (+0.69), PCYC: 256.98 (-0.77), ITEK: 4.80 (-0.02), REDX: (), PTX: 7.44 (-0.05), CLDX: 28.95 (+1.08), ILMN: 190.04 (-9.27), IDGX: (), ACAD: 38.55 (-0.20), TRGT: 2.30 (-0.02), CLLS: 31.30 (-0.91), EXAC: 24.15 (+0.15), ABBV: 64.52 (+0.91), CRMD: 8.86 (-0.28), AGMX: (), ZGNX: 1.63 (-0.02), VVUS: 2.50 (+0.04), SPPI: 5.98 (+0.04), GSK: 46.57 (-0.67), OREX: 7.39 (+0.22), SQNM: 4.47 (+0.08), IRWD: 15.07 (-0.19), GILD: 104.18 (-1.02), MRK: 57.69 (+0.03), OHRP: 2.72 (+0.08), TEVA: 63.01 (-1.15)
